Preview Mode Links will not work in preview mode


Welcome to the Empowered Patient Podcast with Karen Jagoda.  This show is a window into the latest innovations in applying generative AI, novel therapeutics and vaccines, and the changing dynamics in the medical and healthcare environment. One focus is on how providers, pharmaceutical companies, and payers are empowering patients.  In addition, conversations are often about how providers, care facilities, pharmaceutical companies, and payers are being empowered by technology to improve patient outcomes and reduce friction across the healthcare landscape.

Popular Topics

  • Virtual and digital health
  • Use of AI, ML, and LLM in healthcare and drug discovery, development, trials
  • Value-based healthcare 
  • Precision and stratified medicine
  • Integration of digital technology into existing workflow and procedures 
  • Next-generation immuno, cell, and gene therapies
  • Vaccines
  • Biomarkers, sequencing, and imaging
  • Rare diseases
  • MedTech and medical devices
  • Clinical trials
  • Addressing Social Determinants of Health
  • Treating chronic conditions like obesity and pain
  • Clinician and staff burnout

The audience includes life science leaders, researchers, medical professionals, patient advocates, digital health entrepreneurs, patients, caregivers, healthcare solution providers, students, journalists, and investors. 


Check out our new EmpoweredPatient.Solutions site where you can quickly search all of the Empowered Patient Podcast interviews by any word or phrase to identify useful resources, potential partners, and insights about the life sciences landscape.

Empowered Patient Solutions

Jan 31, 2023

Tuvik Beker CEO of Pangea Biomed is looking for more accurate biomarkers for oncology to better determine who might benefit from a specific drug. Their ENLIGHT platform is a pan-cancer, pan-treatment response predictor and can be used to find the best patient populations to give a new drug. They are also working with bio-pharma companies on improving the identification of novel targets through better biomarkers, better patient stratification, and combination therapy optimization.

Tuvik elaborates, "Rather than looking at the genome and looking for abnormalities in gene coding, those rare fusions, or actionable mutations, what Pangea is doing is looking at the way genes are activated in the tumor."

"And this turns out to be a much, much more common abnormality in cancer tumor cells. So almost any tumor cell that you would examine, you would find hundreds and even thousands of genes that are normally encoded. So they have no mutations, they are wild-type genes, and yet they are abnormally expressed in the tumor compared with normal tissue. And the question is, of course, how do we harness this common abnormality of expression into effective therapies? So, there is where our technological uniqueness comes in."

"And that's really what we are hoping for in the long run because ENLIGHT is not only a way to say generally, qualitatively, whether a particular drug would be good or not. It can actually rank and compare different therapies in a way that gives the treating physician a very clear map of what the available treatments are and what should be considered or is the ultimate decision a clinical one. So we are just dealing with treatment elimination but in a very informed manner."

@BekerTuvik @PangeaBiomed #PrecisionMedicine #Oncology #PrecisionOncology #Biotech #Startup

Listen to the podcast here